Print Page | Close Page

 
 

Arcera Life Sciences

Address: International Tower, 3rd Floor, Capital Centre, Abu Dhabi,
 
Country: United Arab Emirates
 
Parent: ADQ
 
Sectors: Collaborations & Partnerships- R&D, Collaborations & Partnerships-Licensing, Collaborations & Partnerships-Manufacture, Distributor, Contract Manufacturing, Distributor, Generic Formulations, Collaborations & Partnerships-Licensing
 
Website: https://www.arceralifesciences.com
 
- - -
 

Social Media

LinkedIn : https://www.linkedin.com/company/arceralifesciences/about/
 
- - -
 

About Us

An international life sciences company focused on pharmaceuticals, operating across partnering, manufacturing medicines and packaging, and marketing health solutions. Commercial operations span four continents including the Middle East, Türkiye, North Africa, Egypt, Sub-Saharan Africa, Ukraine, Eurasian countries, and Latin America.

Arcera is a global company in the life sciences sector that is headquartered in Abu Dhabi, United Arab Emirates. Our vision is to bridge investment, talent, and expertise to become a leader in addressing and mitigating healthcare challenges by offering products that improve the quality and longevity of human life while fostering sustainable growth. With an operational footprint spanning over 90 countries across four continents, we bring together complementary businesses offering 2,000 branded medicines across a wide range of therapeutic areas, supported by a combined workforce of more than 6,500 people. Our businesses: Acino International (Acino) is a pharmaceutical company headquartered in Switzerland with origins dating back to 1836 and manufacturing sites in five countries as well as commercial operations across four continents that develops, manufactures, markets, and distributes a wide range of medicines internationally. To learn more, visit https://acino.swiss Birgi Mefar Group (BMG) is one of Türkiye’s largest sterile production service companies specializing in the manufacturing of sterile injectables and glass packaging, in addition to pharmaceutical distribution services. To learn more, visit https://www.mefar.com Amoun Pharmaceutical Company (Amoun) is a leading pharmaceutical manufacturer headquartered in Egypt specialized in the development, manufacturing, marketing, distribution, and export of a wide range of human pharmaceutical and animal health products. To learn more, visit https://www.amoun.com

 
- - -
 

Sectors

  • Collaborations & Partnerships- R&D
  • Collaborations & Partnerships-Licensing
  • Collaborations & Partnerships-Manufacture
  • Distributor
 
  • Contract Manufacturing
  • Distributor
  • Generic Formulations
  • Collaborations & Partnerships-Licensing
 
- - -
 

Category/Key Word(s)

  • Active Pharmaceutical Ingredients-Generics
  • Finished Dosage
  • Generic Formulations
  • Human Pharmaceuticals
  • Commercial Scale Manufacturing
  • Distributor-Dosage Form
  • Distributor-General
  • Commercialisation Services
  • Licensing
  • Generic Formulations
 
  • Cardiovascular Products
  • Diabetes
  • Injectables
  • Sterile Formulations
  • Anti-Infection Products
  • OTC Products
  • Packaging
  • Supply Chain Management
  • Logistics Solutions
 
- - -
 

Certifications

  • GMP-Gulf Cooperation Council-Inspected
  • ISO 9001- Quality Management
 
  • GMP-World Health Organisation (WHO)
  • GMP Compliance (non-certification)
 
- - -
 

News

 
29th June 2026
 

Arcera Life Sciences and Daewoong Expand Strategic Partnership to Bring Enavogliflozin to the Middle East

 
Expansion builds on successful collaboration across Latin America and reinforces commitment to advancing innovative cardiometabolic therapies across international markets.

Abu Dhabi, United Arab Emirates and Seoul, South Korea - June 29, 2026 - Arcera Life Sciences and Daewoong Pharmaceutical Co., Ltd. announced expansion of their strategic partnership for Enavogliflozin, a novel sodium-glucose cotransporter-2 (SGLT2) inhibitor, into key Middle Eastern markets.

The agreement builds upon successful collaboration established between Daewoong and M8 Pharmaceuticals for Latin America, which became part of Arcera following its December 2024 integration. The companies recently achieved approval of Enavogliflozin in Mexico.

The expansion reflects both companies commitment to increasing patient access to innovative therapies for type 2 diabetes and cardiometabolic conditions across emerging markets. Enavogliflozin is approved in South Korea for treating type 2 diabetes mellitus and demonstrates meaningful efficacy in glycemic control.

Isabel Afonso, CEO of Arcera, stated: At Arcera, we are building a leading life sciences company that connects innovation with patients across international markets.

Shawn Park, CEO of Daewoong, added: This expansion reflects the global competitiveness of Enavogliflozin as a next-generation SGLT2 inhibitor.

The companies will pursue regulatory, market access, and commercialization activities supporting future launches across UAE, Saudi Arabia, Kuwait, Oman, Qatar, Bahrain, Egypt, and Iraq.
 
- - -
 
Printed: 06-Jul-2026 at 19:35:44 hrs
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com